Health-Related Quality of Life of Children and Adolescents with Growth Hormone Deficiency or Idiopathic Short Stature – Part 2: Available Results and Future Directions

Monika Bullinger\textsuperscript{a}  Maria Kołtowska-Häggström\textsuperscript{c,d}  David Sandberg\textsuperscript{g}

John Chapline\textsuperscript{e,f}  Hartmut Wollmann\textsuperscript{h}  Meinolf Noeker\textsuperscript{b}  Anna Levke Brütt\textsuperscript{a}

\textsuperscript{a}Institute for Medical Psychology, University Hospital Hamburg Eppendorf, Hamburg, and \textsuperscript{b}Department of Pediatrics, University of Bonn, Bonn, Germany; \textsuperscript{c}KIMS Medical Outcomes, Pfizer Endocrine Care, Sollentuna, \textsuperscript{d}Department of Pharmacy, Uppsala University, Uppsala, \textsuperscript{e}Gothenburg Pediatric Growth Research Center, and \textsuperscript{f}Department of Pediatrics, The Queen Silvia Children's Hospital, Växthuset, Gothenburg, Sweden;\textsuperscript{g}Department of Pediatrics and Communicable Diseases, Division of Child Behavioral Health, University of Michigan Medical School, Ann Arbor, Mich., USA; \textsuperscript{h}EBT Ophthalmology/Endocrine, Pfizer Ltd., Surrey, UK

Key Words
Growth hormone deficiency \cdot Idiopathic short stature \cdot Quality of life

Abstract
Research on the health-related quality of life (HrQoL) impact of short stature and its treatment in children and adolescents has developed recently. Based on a PubMed literature search, studies addressing this issue were identified and considerable methodological problems mainly related to the HrQoL instruments used and conflicting results are discussed in this mini review. Additionally, this mini review identifies a need for further research and indicates potential directions.

Introduction

Short stature (SS) is a relative concept. It is conventionally defined as a height of two standard deviations (SDs) or more below the mean, or approximately the 3rd percentile [1]. Each year, 90,000 children are born in the USA with a height that, by definition, falls below the 2nd percentile and thereby are considered to have SS. If the less rigid 5th percentile cutoff is used, as is frequently the case in clinical practice, then 150,000 children a year would be classified as having SS, assuming a normal distribution for heights in the general population [2]. SS in children may have different causes, including normal variation, genetic defects, malnutrition, chronic systemic disease, endocrine disorders or psychosocial deprivation. Growth hormone deficiency (GHD) represents a relatively rare cause for SS, which is due to insufficient secretion of growth hormone (GH). However, most youths with SS are GH sufficient based on laboratory tests [3]. The heterogeneous group whose SS is not attributable to underlying pathology is classified as idiopathic short stature (ISS). Definition of ISS involves a height \(-2\) SDs for age and sex and the exclusion of systemic disease [4, 5].

Conflict of Interest Statement: D.S. was a consultant to Pfizer Inc.; H.W. and M.K.-H. are Pfizer employees.
GH therapy is the most effective treatment option to increase growth velocity and adult height in persons with GHD. In many countries, GH is an approved treatment not only for children with GHD, but also for Turner syndrome, renal failure, children born small for gestational age, and Prader-Willi syndrome. Children with ISS exhibit increased growth with GH treatment [4, 6] and the US Food and Drug Administration approved this indication in 2003. Results of GH studies in ISS show an average gain in adult height of approximately 4–6 cm [4]. In a recent Cochrane Review, Bryant et al. [7] concluded that GH therapy in ISS can increase short-term growth and adult height. However, patients remain relatively short compared to peers.

Since it is not yet clear which benefits are associated with GH treatment, and specifically if GH-induced height gain is associated with changes in health-related quality of life (HrQoL), research should address these HrQoL outcomes, especially focusing on measures that can be used in economic modeling [7, 8]. Interest in HrQoL, as an indicator of patient-reported health outcomes and benefits, has extended to pediatric populations, and studies are available, especially in the area of chronic disease in children and adolescents. In children with SS, psychological research has focused on functioning and performance rather than on well-being and adaptation.

Studies of impairments associated with SS do not often specifically address ISS, but are often confounded with conditions in which SS is a feature of a phenotype specific to a particular medical condition or syndrome. In a review limited to children with SS (as the major diagnosis), Wheeler et al. [9] concluded that short children scored lower than their peers on intelligence tests, academic achievement and behavioral adaptation, but the scores fell within the normative range (1 SD). Deficits for youths with SS were reported in visual-motor skills as well as psychological, educational and behavioral functioning [9]. Nonetheless, it remains unclear whether the deficits are the consequence of an underlying condition causing SS, or cognitive and psychological sequelae. Taking into account other studies on SS and functional impairment, no direct link has been found [10, 11].

Psychosocial effects of SS have been reported to include stigmatization and social isolation due to stature-related stereotypes [12, 13]. Some studies report that short children experience chronic psychosocial stress [14, 15], although these experiences do not generally result in clinically significant problems of psychosocial adaptation [13, 10].

The recent literature is inconclusive with regard to whether or not SS, per se, is a handicapping condition. Furthermore, emotional problems secondary to teasing or low self-esteem have not been unequivocally confirmed [15, 16]. According to parent reports, short children exhibit lower social competencies and more problems in social interaction than children with stature within the normative range [17]. Other studies, however, have failed to detect deficits in academic or psychosocial functioning among children with SS [10, 18].

Risk factors potentially affecting psychosocial adaptation among those with SS include male gender, the presence of a younger but taller sibling, being perceived and treated as younger than chronological age, lower intelligence, and lower family socioeconomic status [17]. As many of these constitute ‘risk factors’ for children with average stature, they are not specific for those with SS.

Thus it remains unclear why some children with SS develop psychologically well and others do not [19, 20].

**HrQoL Research in Children and Adolescents with ISS and GHD Studies of QoL, Patient Preferences and Patient Satisfaction**

If HrQoL is thought to be an important consideration in treatment decisions for children with ISS, studies including validated HrQoL measures are needed. However, such studies are rare at this time [11, 21]. A review of studies examining the influence of SS and GH treatment reveals that investigations have not systematically analyzed findings separately for GHD and ISS (previous article).

A PubMed literature search resulted in only 13 articles using the key words ‘idiopathic short stature’ and ‘quality of life’. Even fewer articles were found when combining ISS with the terms ‘preferences’ (0) or ‘patient satisfaction’ (2). Limiting the search to ‘growth hormone defi-

---

**Table 1. Literature search for articles in the PubMed database**

<table>
<thead>
<tr>
<th></th>
<th>ISS</th>
<th>GHD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quality of life</td>
<td></td>
<td></td>
</tr>
<tr>
<td>All</td>
<td>13</td>
<td>236</td>
</tr>
<tr>
<td>Children</td>
<td>12</td>
<td>72</td>
</tr>
<tr>
<td>Preferences</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Patient satisfaction</td>
<td></td>
<td></td>
</tr>
<tr>
<td>All</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>Children</td>
<td>1</td>
<td>2</td>
</tr>
</tbody>
</table>
### Table 2. Studies assessing HrQoL in children and adolescents with SS

<table>
<thead>
<tr>
<th>Study</th>
<th>Instrument</th>
<th>Respondent</th>
<th>Sample size</th>
<th>Sample</th>
<th>Sample source</th>
<th>Age</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>QoL in patients with growth disorders (including GHD and ISS)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leiberman et al. [22]</td>
<td>QoL</td>
<td>children</td>
<td>n = 96</td>
<td>GH treatment GHD: 15</td>
<td>hospital setting</td>
<td>8–16 years</td>
</tr>
<tr>
<td>Pilpel et al. [23]</td>
<td></td>
<td></td>
<td></td>
<td>ISS: 65; TS: 16 not treated: 33</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sandberg et al. [24]</td>
<td>CBCL</td>
<td>parent</td>
<td>n = 258</td>
<td>SS</td>
<td>hospital setting</td>
<td>4–18 years</td>
</tr>
<tr>
<td>Cramer et al. [25]</td>
<td>VSP-AM</td>
<td>children</td>
<td>n = 172</td>
<td>GHD: 125; ISS: 19; TS: 17 unknown: 11</td>
<td>GH treatment</td>
<td>11–19 years</td>
</tr>
<tr>
<td>Norby et al. [26]</td>
<td>CHQ</td>
<td>child, parent</td>
<td>n = 51</td>
<td>SS</td>
<td>hospital setting</td>
<td>9–16 years</td>
</tr>
</tbody>
</table>

**Studies on GH treatment in ISS patients**

<table>
<thead>
<tr>
<th>Study</th>
<th>Instrument</th>
<th>Respondent</th>
<th>Sample size</th>
<th>Sample</th>
<th>Sample source</th>
<th>Age</th>
</tr>
</thead>
<tbody>
<tr>
<td>Theunissen et al. [30]</td>
<td>TNO-AZL TACQOL ISSQOL DUCATQOL</td>
<td>parent, child</td>
<td>n = 36</td>
<td>ISS; GH treatment: 20 control: 20</td>
<td>randomized clinical trial</td>
<td>4–10 years (at start)</td>
</tr>
<tr>
<td>Ross et al. [27]</td>
<td>CBCL</td>
<td>parent</td>
<td>n = 59</td>
<td>ISS; GH treatment: 33 placebo: 26</td>
<td>clinical setting</td>
<td>9–16 years</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>SPP</td>
<td>child</td>
<td>n = 59</td>
<td>ISS; GH treatment: 32 placebo: 27</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Studies on GH treatment in GHD patients**

<table>
<thead>
<tr>
<th>Study</th>
<th>Instrument</th>
<th>Respondent</th>
<th>Sample size</th>
<th>Sample</th>
<th>Sample source</th>
<th>Age</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mauras et al. [32]</td>
<td>QoL-AGDHA</td>
<td>adolescents</td>
<td>n = 55</td>
<td>GHD; GH treatment: 25 placebo: 15; control: 15</td>
<td>hospital setting</td>
<td>mean: 15.8</td>
</tr>
<tr>
<td>Sheppard et al. [31]</td>
<td>PedsQL</td>
<td>parent, children</td>
<td>n = 22</td>
<td>GHD; acquired GHD: 14 idiopathic GHD: 8</td>
<td>clinical setting</td>
<td>8–16 years</td>
</tr>
<tr>
<td>Lagrou et al. [37]</td>
<td>QoL-AGDHA</td>
<td>adult (retrospective)</td>
<td>n = 36</td>
<td>GHD; isolated GHD: 26 multiple GHD: 10</td>
<td>clinical setting</td>
<td>mean: 20.0</td>
</tr>
</tbody>
</table>

C = Children; P = parents; CBCL = Child Behavior Checklist [44]; VSP-AM = Vecu et Santé Perçue de l’Adolescent [45]; CHQ = Child Health Questionnaire [46]; ISSQOL = Idiopathic Short Stature QoL Questionnaire; TACQOL = TNO AZL Children’s Quality of Life [47]; DucatQoL = Dutch Children’s AZL/TNO Quality of Life Questionnaire [48]; SSP = Self-Perception Profile [49]; QLS-H = Questions on Life Satisfaction-Hypopituitarism [36]; QoL-AGDHA = Quality of Life-Assessment of Growth Hormone Deficiency in Adults [34]; PedsQoL = Pediatric Quality of Life Inventory [50].
<table>
<thead>
<tr>
<th>Study aim</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>QoL and SS</td>
<td>No differences with respect to gender, underlying disease or onset or duration of treatment</td>
</tr>
<tr>
<td>effects of treatment on QoL</td>
<td>No differences in QoL between GH-treated and nontreated groups</td>
</tr>
<tr>
<td>QoL and SS</td>
<td>Boys were less socially competent and had more behavioral and emotional problems by parent report; boys rated themselves as less socially active, all other boys scores and girls score were within normative range</td>
</tr>
<tr>
<td>psychometric testing</td>
<td>Better VSP-AM QoL scores for all subscales and total except for self esteem compared to medical, surgical or psychiatric comparison groups</td>
</tr>
<tr>
<td>psychometric testing</td>
<td>Highest QoL in SS compared to juvenile chronic arthritis, diabetes and asthma, expect self-esteem (C, P) and behavior (P)</td>
</tr>
<tr>
<td>QoL effects of GH therapy</td>
<td>HrQoL comparable to population, except lower scores in social functioning (C, P), no improvement of HrQoL during treatment</td>
</tr>
<tr>
<td>QoL effects of GH therapy</td>
<td>Behavioral scores comparable to population norms at baseline; differences between treatment and control group observed in year 4 after substantial participant dropout</td>
</tr>
<tr>
<td>QoL effects of GH therapy</td>
<td>Baseline scores within normal range, and no subsequent differences between groups</td>
</tr>
<tr>
<td>QoL effects of GH therapy</td>
<td>Baseline QoL scores in the lower normal range; differences were found in ability to become sexually aroused, ability to tolerate stress, ability to concentrate, self confidence, physical endurance and body shape and appeared to respond positively to GH treatment</td>
</tr>
<tr>
<td>QoL effects of GH therapy</td>
<td>Normal HrQoL when reaching adult height, continuation of GH replacement not associated with improvements relative to placebo or control group</td>
</tr>
<tr>
<td>QoL effects of GH therapy</td>
<td>AGHD QoL below population norms and improved QoL over time; no significant results for idiopathic GHD children</td>
</tr>
<tr>
<td>retrospective perception of QoL effect of GH therapy</td>
<td>Patients initiating GH treatment after the age of 12 complained about difficulties in self-confidence, social contact and contact with the opposite sex and emotional life</td>
</tr>
</tbody>
</table>
ciency’ or ‘GH deficiency’ and ‘quality of life’, 236 articles were found, of which 72 concerned children. Additionally, four studies on ‘patient satisfaction’ were found and only one study on patient ‘preferences’ (table 1). Articles on GH treatment are more common, particularly those that focus on adult height attained [7]. Although the construct of HrQoL may have been mentioned in many of these studies, only a few adequately measured HrQoL; these are described in detail below (table 2). The key word search strategy employed in this mini review restricted studies to those specifically taking into account HrQoL. Studies of psychosocial adaptation or related constructs were not included in the search strategy.

QoL in Patients with Growth Disorders (Including GHD and ISS)

Leiberman et al. [22] were the first to assess patient satisfaction in GH-treated children with SS. They incorporated their own HrQoL questionnaire which included an assessment of coping and satisfaction with GH treatment. Ninety-six children (65 without underlying medical conditions, 15 with GHD and 16 with Turner syndrome) filled out the questionnaire during a regular endocrinology visit. Results revealed that patients tolerated treatment, coped well, and expressed satisfaction with it. Differences between patients with and without underlying medical conditions were not found. Additionally, a cross-sectional comparison of GH-treated patients with a nontreated control group did not detect differences in school achievements, leisure activities, emotional and physical self-esteem, relationships with peers or family members [23]. In another heterogeneous sample of 180 boys and 78 girls with growth disorders, boys were rated by a parent as less socially competent and exhibiting more behavioral and emotional problems than a normative sample. However, they were significantly more socially competent and showed fewer psychopathologic symptoms than a psychiatric-referred sample of comparable age. Girls in the same study were comparable to the normative group according to both parent and self-report [24]. Similarly, Cramer et al. [25] reported a better QoL of patients with growth disorders (GHD: 125, ISS: 19, Turner Syndrome: 17, other related diagnoses: 9) compared to patients with medical, surgical or psychiatric disorders, except for the self-esteem domain. Another study of patients with SS reported higher HrQoL in physical function, bodily pain and general health perceptions compared to groups with chronic illness. Ratings on the dimensions of self-esteem and behavior did not differ from patients with asthma or diabetes [26].

Studies of GH Treatment in ISS Patients

Ross et al. [27] randomly assigned 68 children to receive either GH or placebo. A trend towards reduced behavior problem was observed in the treated group, but only by parent report and for the very limited subset of patients who remained in the study in its final (fourth) year (GH-treated n = 9; placebo n = 3). Effects of GH on parent-reported social competencies or participant ratings of self-concept were not observed.

Theunissen et al. [28] reported that children with ISS did not generally exhibit impairments in QoL measured by the TNO AZL Children’s Quality of Life [29] self-report questionnaire, the social functioning domain being the exception. When comparing GH-treated and untreated children, pediatricians providing the care reported improved HrQoL in the treatment group; parent and child ratings, however, did not differ between treatment and control groups. Instead, perceived height and satisfaction with current height were associated with higher HrQoL ratings and self-esteem [28]. To date this is the only study in children with ISS which used a combination of generic (TNO AZL Children’s Quality of Life) and condition-specific (Idiopathic Short Stature QoL [30]) measures.

Studies of GH Treatment in GHD Patients

Sheppard et al. [31] examined parents and self-reports of QoL among 14 children with idiopathic GHD and 8 with acquired GHD (following a malignancy and its treatment) before and after 6 months of GH treatment. Ratings for patients with acquired GHD were significantly below population norms before and improved with treatment, whereas the subgroup with idiopathic GHD did not show significant changes in QoL.

The transition from pediatric to adult health care is of special importance. Accordingly, the correspondence between measures and study results for children and adults is important to evaluate. In a study examining the metabolic and HrQoL benefits of GH during the transition to the adult phase of treatment in adolescents with GHD, Mauras et al. [32] employed both generic (Short Form 36 Health Survey [33]) and condition-specific (Quality of Life-Assessment of Growth Hormone Deficiency in Adults [34]) HrQoL measures in a double-blind, placebo-controlled study. At near completion of linear growth, and while still on treatment, mean HrQoL scores on the generic measure did not differentiate the GHD patients from general population norms. Furthermore, GH treatment over the subsequent 2 years was not associated with changes in generic or condition-specific HrQoL scores compared to the placebo control group.
Studies in adolescents and young adults have also employed adult condition-specific questionnaires to measure HrQoL. In a multinational study examining the transition phase of GH treatment following attainment of adult height, Attanasio et al. [35] randomly assigned patients with childhood onset GHD to three groups: continuation of GH therapy at two different dosages and an untreated control group. Study participants completed the Questions on Life Satisfaction-Hypopituitarism [36] questionnaire at baseline and annually for 2 years. Mean total scores at baseline fell in the low-normal range for the general population. However, scores on individual subscale items (e.g. perceptions of body shape, physical endurance, and self-confidence) were significantly lower than norms. GH treatment, at either dose, was not associated with an improvement in Questions on Life Satisfaction-Hypopituitarism scores compared to the untreated control group, but a within-group improvement in scores from baseline to 2 years was observed for the GH-treated groups (dosage subgroups combined) on the items ‘ability to become sexually aroused’ and ‘body shape’, relative to the untreated control group.

Lagrou et al. [37] examined psychosocial and QoL outcomes following GH therapy in 36 young adult patients (18–23 years) with childhood onset GHD (including both isolated GHD and multiple pituitary hormone deficiency subgroups). Those patients who were shorter at the initiation of treatment reported lower HrQoL (Quality of Life-Assessment of Growth Hormone Deficiency in Adults) scores as young adults (r = –0.43). Further, those participants who had initiated hormone replacement after the age of 12 reported significantly more difficulties with self-confidence and social relations during a semi-structured interview than those starting treatment at an earlier age. This same subgroup reported a significantly increased likelihood of rating the timing of their pubertal onset as ‘too late’. The subset of patients with multiple pituitary hormone deficiencies (n = 10) were described by self- and parent report as experiencing more problems in life adjustment during childhood and in the present compared to patients (n = 26) with isolated GHD. Despite attaining adult heights comparable to mid-parental height (–0.5 ± 0.9 SDs), a substantial proportion of participants’ parents (higher in the multiple pituitary hormone-deficient group) anticipated that their child would experience difficulties in finding a job, leaving home, and developing a stable romantic relationship.

Health utility measures such as the EQ5D or the HUI have not yet been used in pediatric populations.

**Discussion**

HrQoL is increasingly considered as a relevant outcome in ISS and GHD and an important endpoint in GH treatment. As this mini review has demonstrated, HrQoL in ISS/GHD has been the focus of studies only for a relatively short time.

**Generic and Condition-Specific HrQoL Assessment**

Generic assessment methods were most frequently adopted for use in both adult and pediatric samples. The literature review showed that HrQoL in youths with ISS or GHD was comparable to the general population [9, 12–14]. This is possibly because the measures commonly employed in such research were generic in nature and the impact of physical development on HrQoL may have been underestimated or not taken into consideration at all.

**Self- and Proxy Ratings**

The current mini review also highlighted the limited concordance between parent and child ratings. While parents of short children commonly report problems of cognitive development, personality, self-esteem or social relations, their children do so only sporadically. Although some studies assessed behavior and adaptation by both self- and proxy report [26, 38], the correlation between child- and parent-rated HrQoL has yet to be systematically examined.

Utilizing peers as a source of information about the child’s psychosocial adaptation is another source of information deserving serious consideration. The problems purported to stem from SS are believed to be linked to negative social interactions in the peer group, and yet there exists only limited research that has directly examined peer relations among youths with SS [39, 40].

**Importance of Height**

A fundamental issue for pediatric outcome assessment in GHD and ISS is the importance of height to experienced HrQoL, and the relation between measured height gained and changes in HrQoL. A child’s or adolescent’s satisfaction with his/her own height is influenced by social perceptions (e.g. parent expectations, peer stigma). Accordingly, as has been shown in pediatric psychology, HrQoL can be affected not only by treatment, but also by supporting positive psychological adaptation and through modification of aspects of the proximal social environment [41–43].
Future Directions

A challenge for further research is to unravel the relative contributions of height, perceived height, and psychosocial adaptation to QoL in children with SS. The ultimate aim of such investigation is to better understand what life is like for these children and to examine the impact of SS and its treatment on patient-reported well-being and functioning.

Acknowledgment

This literature review was supported by a grant to M.B. from Pfizer Inc.

References


HrQoL of Children and Adolescents with GHD or ISS


40 Sandberg DE, Bukowski WM, Fung CM, Noll RB: Height and social adjustment; are extremes a cause for concern and action? Pediatrics 2004;114:744–750.


